Podcasts about mll

Hey Podtimists,This week David goes to Oakland and plays a video game, then Chase plays Nubby's Number Factory and learns what it's like to log on to CoolMathGames.com.We also took a deeper look at the legendary Gran Turismo 2. That game was suggested to us my listener MLL, thanks MLL!---Timestamps:(0:00) - Intro(4:58) - What David has been playing(6:22) - Cat Quest 3(6:46) - Hero Realms(10:20) - We can talk about the Switch 2 as a little treat(31:51) - What Chase has been playing(31:58) - Nubby's Number Factory(39:14) - Dark Deity 2(50:33) - JK David wants to talk about Hollow Knight(53:10) - Chase's Podtimistic thing of the week(55:17) - David's Podtimistic thing of the week(57:11) - Good Games! Featuring Gran Turismo 2(1:21:46) - Outro---Games mentioned:Cat Quest 3Hero RealmsNubby's Number FactoryDark Deity 2Hollow KnightGran Turismo 2

US-Zölle - die Folgen für die EU: Dazu der Ökonom Prof. Michael C. Burda; Wie geschwächt ist Marine Le Pen? Ein Gespräch mit Dr. Eileen Keller vom Deutsch-Französischen Institut Ludwigsburg; Müllberge in Birmingham; "Denk‘ ich an Europa“ mit der Autorin Maike Albath: “Für mich ist Europa die größte Errungenschaft“; Mod.: Andrea Oster. Von WDR 5.

Das Bild vieler Städte in Nordrhein-Westfalen hat sich stark verändert. Und Viele fragen sich: Was passiert mit meiner Stadt? Wie kann ich helfen? Was muss passieren? Moderation: Jürgen Wiebicke Von WDR 5.

Heute mit Trude und ihrem Tier beim Ausmisten, neuen und alten Dingen und natürlich mit der Maus. Von WDR.

Außerdem: Eier essen - Was jetzt, gesund oder ungesund? (14:35)// Mehr spannende Themen wissenschaftlich eingeordnet findet Ihr hier: www.quarks.de // Habt Ihr Feedback, Anregungen oder Fragen, die wir wissenschaftlich einordnen sollen? Dann meldet Euch über Whatsapp oder Signal unter 0162 344 86 48 oder per Mail: quarksdaily@wdr.de. Von Sebastian Sonntag.

Die Streikwelle führt in Darmstadt zu überfüllten Mülltonnen, der Zustand der Rheinstraßenbrücke ist weiterhin miserabel und trotz Masernimpfpflicht sind nicht ausreichend Kinder geimpft. Das und mehr heute im Podcast. Alle Hintergründe zu den Nachrichten des Tages finden Sie hier: https://www.echo-online.de/lokales/darmstadt/wegen-streikwelle-darmstadt-stellt-muellcontainer-auf-4445586 https://www.echo-online.de/lokales/darmstadt/der-zustand-der-rheinstrassenbruecke-in-darmstadt-ist-weiterhin-miserabel-4397326 https://www.echo-online.de/politik/politik-hessen/warum-hessen-dieses-jahr-nur-zwei-wochen-osterferien-hat-4440906 https://www.echo-online.de/lokales/kreis-darmstadt-dieburg/landkreis-darmstadt-dieburg/gelbe-saecke-wie-geht-es-weiter-nach-dem-ultimatum-4422817 https://www.echo-online.de/ratgeber/gesundheit/masernimpfung-quoten-trotz-impfpflicht-zu-niedrig-4439558 Ein Angebot der VRM.

Dr. John Sweetenham and Dr. James Foran discuss the evolving treatment landscape in acute myeloid leukemia, including new targeted therapies, advances in immunotherapy, and the current role for allogeneic transplantation. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. There has been steady progress in the therapies for acute myeloid leukemia (AML) in recent years, largely based on an increasing understanding of the molecular mechanisms which underlie the disease. On today's episode, we'll be discussing the evolving treatment landscape in AML. We'll explore risk group stratification, new targeted therapies, advances in immunotherapy for AML, and also a little about the current role for allogenic transplantation in this disease.  I'm delighted to welcome Dr. James Foran to this discussion. Dr. Foran is a professor of medicine and chair of the Myeloid Malignancies and Blood and Marrow Transplant Disease Group at the Mayo Clinic Comprehensive Cancer Center. He's based in Jacksonville, Florida.  Our full disclosures are available in the transcript of this episode.  James, it's great to have you join us on the podcast today, and thanks so much for being here. Dr. James Foran: I'm delighted and thank you for the invitation. Thank you very much. Dr. John Sweetenham: Sure, James, let's get right into it. So, our understanding of the molecular mechanisms underlying AML has resulted not only in new methods for risk stratification in this disease, which have added refinement to cytogenetics, but also has resulted in the development of many new targeted agents. Understanding that this is a complex area of investigation, and our time is somewhat limited, can you give us a high-level update on the current state of the art in terms of how risk factors are being used for treatment selection now? Dr. James Foran: Absolutely. I think in the past, you know, we had things broken down pretty simply into make a diagnosis based on morphology, do cytogenetics, break patients into the groups of those who were more likely to benefit from therapy – so-called favorable risk – those where the intensive therapies were less likely to work – so-called poor adverse risk, and then this large intermediate group that really had variable outcomes, some better, some worse. And for a long time, the progress was in just identifying new subtle cytogenetic risk groups. And then, late 1990s, we began to understand that FLT3 mutations or NRAS mutations may be more adverse than others that came along. In the first part of this millennium, in the, you know, 2000-2010 range, a lot of work was being done to understand better or worse risk factors with single genes. The ability to do multiplex PCR, and then more recently NGS platforms, have allowed us to really look at many genes and identify many mutations in patients. At the beginning that was used just to sort of refine – who did a little better, who did a little worse with intensive therapy – helped us decide who may benefit more from an allogeneic transplanter for whom that would not be necessary.  But the good news is that really, we're now starting to target those mutations. One of the first molecularly targeted treatments in leukemia was FLT3 mutations, where we knew they were adverse. Then along came targeted treatments. I was involved in some of those early studies looking at sunitinib, sorafenib, more recently midostaurin, now quizartinib, FDA approved, and gilteritinib in the relapse refractory setting.  So we're moving into a state where we're not just refining prognosis, we're identifying targets. You know, it's been slow progress, but definite incremental progress in terms of outcomes by looking for FLT3 mutations, then looking for IDH mutations, and more recently, mutations involving NPM1 or rearrangement of what we used to call the MLL gene, now the lysine methyltransferase 2A or KMT2A rearrangement, where we now have targets. And it's not just for refinement of prognosis, but now we're identifying therapeutic targets for patients and ways to even look for measurable residual disease which is impacting our care. Dr. John Sweetenham: That's great, James. And I'm going to expand on that theme just a little bit and perhaps ask you to elaborate a little bit more on how the introduction of these new therapies have specifically impacted frontline therapy. And a couple of ancillary questions maybe to go along with that: First of all, is ‘7+3' a standard therapy for anybody in 2025? And maybe secondly, you know, could you comment also maybe briefly on older patients with AML and how you think maybe the treatment landscape is changing for them compared with, say, 5 or 10 years ago? Dr. James Foran: I'll start with the therapy and then work my way back. So we've had ‘7+3' cytarabine daunorubicin or cytarabine anthracycline since 1976, and we're still using it as the backbone of our intensive therapy. There is still an important role for it, particularly in younger or fitter patients, and particularly for those with intermediate or favorable risk genetic groups or cytogenetic risk groups just because we achieve high rates of remission. Our 30-day induction mortality rates are lower now than they were 10 and 20 years ago. Our supportive care is better. And we still have a busy inpatient hospital service here at Mayo Florida and my colleagues in Rochester and Arizona as well giving intensive therapy. So that remains the backbone of curative therapy for younger adults. We are trying to be a little more discriminating about who we administer that to. We are trying to add targeted agents. We know from, now, two different randomized trials that the addition of a FLT3 inhibitor, either midostaurin or more recently quizartinib, has a survival advantage in patients with a FLT3 mutation, or for quizartinib, a FLT3/ITD mutation. And so yes, ‘7+3' remains important.  Off protocol for somebody who just comes in with acute leukemia in a 40-year-old or 30-year-old or even early 60s and fit, we would still be considering ‘7+3' therapy and then waiting for an expedited gene mutation panel and an expedited cytogenetics panel to come back to help us discriminate is that a patient for whom we should be giving a FLT3 inhibitor? I think there's a little more nuance about when we do a day 14 bone marrow, do they really matter as much anymore? I still do them. Some of my colleagues find them less important. But we're still giving intensive therapy. We're still giving high-dose ARA-C consolidation for younger patients who achieve complete remission.  In older adults, it's a different story. You know, it was only in the early part of the 2000s – 2004, 2007 range – where we really got buy-in from randomized studies that low-dose therapy was better than no therapy. There was a lot of nihilism before then about therapy for older adults, especially over age 75. We know that low-dose ARA-C is better than nothing. It looked like azacitidine was better than ARA-C or at least equivalent or slightly better. But with the advent of venetoclax it was a game changer. I ran a national randomized study of intensive therapy in AML. It was the last national randomized study of intensive therapy in older patients right before venetoclax got approved. And we were very excited about our results, and we thought we had some really interesting clinical results. And suddenly that's a little bit obsolete in patients over 70 and particularly over age 75 because of the high remission rates with azacytidine venetoclax or hypomethylating agents, so-called HMAs and venetoclax and the survival advantage. Now, it's not a home run for everybody. We quote 60% to 70% remission rates, but it's a little different based on your cytogenetics and your mutation profile. You have to continue on therapy so it's continuous treatment. It's not with curative intent, although there are some people with long-term remission in it. And the median survival went from 10 months to 15 months. So home run? No, but definitely improved remissions, meaningful for patients off transfusions and better survival. So right now it's hard to find an older adult who you wouldn't give azacitidine and venetoclax or something similar, decitabine, for instance, and venetoclax, unless somebody really was moribund or had very poor performance status or some reason not to. And so ‘7+3' is still relevant in younger adults. We're trying to get better results with ‘7+3' by adding targeted agents and azacitine and venetoclax in older adults.  I think the area of controversy, I guess there are two of them, is what to do in that overlap age between 60 and 75. Should people in that age still get intensive therapy, which we've used for years – the VIALE-A trial of aza-venetoclax was age 75 plus – or with cardiac comorbidities? And I think if you're 68 or 72, many of us are starting to bias towards aza-venetoclax as generally being better tolerated, generally being more outpatient, generally being slow and steady way to get a remission. And it doesn't stop you from going to transplant for somebody who might still be a candidate.  The other area of controversy is somebody under 60 who has adverse cytogenetics where we don't do very well with ‘7+3,' we still give it and we might do just as well with decitabine venetoclax. A lot of us feel that there's equipoise in the 60 to 75 group where we really can ask a question of a randomized study. Retrospective studies might suggest that intensive therapy is a little better, but there are now a couple of randomized studies happening saying, “Can we replace ‘7+3' in that intermediate age with aza-venetoclax?” And for younger adults similarly, we're looking to see how we apply that technology. Those are the areas where we're really trying to investigate what's optimal for patients and that's going to require randomized trials. Dr. John Sweetenham: Oh, that's great, thank you. And I'll just extend that question a little bit more, particularly with respect to the new targeted therapies. How much are they impacting the treatment of these patients in the relapse and refractory setting now? Dr. James Foran: Oh, they're definitely impacting it. When I trained and probably when you trained, AML was still a medical emergency. But that was the thing that you admitted to the hospital immediately, you started therapy immediately. The rule was always that's the one thing that brings the fellow and the consultant in at night to see that new patient on a Friday or Saturday. Now, we'll still admit a patient for monitoring, but we try not to start therapy for the first three or five or seven days if they're stable, until we get those genetics and those genomics back, because it helps us discriminate what therapy to pursue. And certainly, with FLT3 mutations, especially FLT3/ITD mutations, we're adding FLT3 inhibitors and we're seeing a survival advantage. Now, on the surface, that survival advantage is in the range of 7% or 10%. But if you then pursue an allogeneic transplant in first remission, you're taking disease where we used to see 30%, 40% long-term survival, maybe less, and you're pushing that to 60%, 70% in some studies. And so we're now taking a disease that– I don't want to get off topic and talk about Ph+ ALL. But that's a disease where we're actually a little excited. We have a target now, and it used to be something really adverse and now we can do a lot for it and a lot about it.  The other mutations, it's a little more subtle. Now, who knew until 2010 that a mutation in a sugar metabolism gene, in isocitrate dehydrogenase, or IDH was going to be so important, or even that it existed. We know that IDH1 and IDH2 mutations are still a minority of AML, certainly less than 10% to 15%, maybe overall. But we're able to target those with specific IDH1 and IDH2 inhibitors. We get single-agent responses. There are now two approved IDH1 inhibitors on the market. We don't yet have the randomized data that adding those to intensive therapy is better, but we're getting a very strong hint that it might be better in older adults who have an IDH mutation, maybe adding those is helpful and maybe adding those to low-intensity therapy is helpful. Those studies are ongoing, and we're also trying with low-intensity treatments to add these agents and get higher remission rates, deeper remissions, longer remissions. I think a lot of work has to be done to delineate the safety of that and the long-term efficacy. But we're getting hints it's better, so I think it is impacting.  The other area it's impacting is when you pick up adverse mutations and those have crept into our classification systems like an ASXL1 mutation or RUNX1 mutation for instance, or some of the secondary AML mutations like BCOR and others, where that's helping us discriminate intermediate-risk patients who we think aren't going to do as well and really helping us select a group who's more likely to get benefit from allogeneic transplant or for whom at least our cure rates without allo transplant are low. And so I think it's impacting a lot. Dr. John Sweetenham: Great. And I'm going to pick up now, if I may, on a couple of things that you've just mentioned and continue the theme of the relapsed and refractory setting. We've started to see some reports which have looked at the role of immune strategies for patients with AML, in particular CAR T or NK cells. Can you comment a little on this and let us know whether you think either these two strategies or other immune strategies are likely to have a significant role in AML in the future? Dr. James Foran: They are, but I think we're still a step behind finding the right target or the right way to do it. If you think of allogeneic transplantation as the definitive immune therapy, and we know for adverse AML we can improve survival rates and cure rates with an allotransplant, then we know inherently that immune therapy matters. And so how do we do what they've done in large cell lymphoma or in CD19 targeting for B cell malignancies? How do we bring that to acute myeloid leukemia? There have been a number of efforts. There have been at least 50 trials looking at different targets. CD33, CD123, CD7, others, CLL-1. So, there have been a number of different trials looking at how to bind a CAR T or a CAR T construct that can be active. And we have hints of efficacy. There was kind of a provocative paper in the New England Journal of Medicine a year ago in April of last year from a Chinese group that looked at a CD7-based CAR T and it was 10 patients, but they used CD7 positive acute leukemia, AML or ALL and had a CD7-targeted CAR T and they actually incorporated that with a haploidentical transplant and they had really high remission rates. People tolerated it quite well. It was provocative. It hasn't yet been reproduced on a larger scale, but the strong hints that the strategy is going to work.  Now, CD33 is a little tricky to have a CAR T when CD33 is expressed on normal hematopoietic cells. CD123 likewise. That's been something where there's, I think, still promise, but we've struggled to find the trials that make that work. Right now, there's a lot of interest in leveraging NK cells and looking, for a couple of reasons, but NK cells are attractive and NK cell markers might be attractive targets. NK cells might have similar degrees of immune efficacy. It's speculative, but they are likely to have less cytokine release syndrome and less neurotoxicity than you see with CAR T. And so it's kind of attractive to leverage that. We have had some ongoing trials looking at it with bispecifics and there certainly are trials looking at it with CAR NK-based strategies. One of the antigens that people looked at is the NK group 2D. NK group 2D or NKG2D is overexpressed in AML and its ligands overexpressed. And so that's a particular potential target. So, John, it's happening and we're looking for the hints of efficacy that could then drive a pivotal trial to get something approved.  One of the other areas is not restricting yourself just to a single antigen. For instance, there is a compound that's looking at a multi-tumor-associated antigen-specific T-cell therapy, looking at multiple antigens in AML that could be overexpressed. And there were some hints of activity and efficacy and actually a new trial looking at a so-called multi-tumor associated antigen-specific T cell therapy. So without getting into specific conflicts of interest or trials, I do think that's an exciting area and an evolving area, but still an investigational area. I'll stop there and say that we're excited about it. A lot of work's going there, but I'm not quite sure which direction the field's going to pivot to there. I think that's going to take us some time to sort out. Dr. John Sweetenham: Yeah, absolutely. But as you say, exciting area and I guess continue to watch this space for now.  So you've mentioned allogeneic stem cell transplants two or three times during this discussion. Recognizing that we don't have an imatinib for AML, which has kind of pushed transplant a long way further back in the treatment algorithm, can you comment a little on, you know, whether you think the role of stem cell transplantation is changing in AML or whether it remains pretty much as it was maybe 10 years ago? Dr. James Foran: By the way, I love that you use imatinib as an introduction because that was 6 TKIs ago, and it tells you the evolution in CML and you know, now we're looking at myristoyl pocket as a target, and so on. That's a great way to sort of show you the evolution of the field.  Allogeneic transplant, it remains a core treatment for AML, and I think we're getting much smarter and much better about learning how to use it. And I'm just going to introduce the topic of measurable residual disease to tell you about that. So I am a little bit of a believer. Part of my job is I support our allogeneic transplant program, although my focus is acute myeloid leukemia, and I've trained in transplant and done it for years and did a transplant fellowship and all that. I'm much more interested in finding people who don't need a transplant than people who do. So I'm sort of looking for where can we move away from it. But it still has a core role. I'll sidestep and tell you there was an MDS trial that looked at intermediate or high-risk MDS and the role of allogeneic transplant that shows that you about double your survival. It was a BMT CTN trial published several years ago that showed you about double your three-year survival if you can find a donor within three months and get to a transplant within six months. And so it just tells you the value of allotransplant and myeloid malignancy in general. In AML we continue to use it for adverse risk disease – TP53 is its own category, I can talk about that separately – but adverse risk AML otherwise, or for patients who don't achieve a really good remission. And I still teach our fellows that an allotransplant decreases your risk of relapse by about 50%. That's still true, but you have to have a group of patients who are at high enough risk of relapse to merit the non-relapse mortality and the chronic graft versus host disease that comes with it. Now, our outcomes with transplant are better because we're better at preventing graft versus host disease with the newer strategies such as post-transplant cyclophosphamide. There are now new FDA-approved drugs for acute and chronic graft versus host disease, ruxolitinib, belumosudil, axatilimab now. So we have better ways of treating it, but we still want to be discriminating about who should get it.  And it's not just a single-minded one-size-fits-all. We learned from the MORPHO study that was published in the JCO last year that if you have FLIT3-positive AML, FLIT3/IDT-positive AML, where we would have said from retrospective studies that your post-transplant survival is 60% give or take, as opposed to 15% or 20% without it, that we can discriminate who should or shouldn't get a transplant. Now that trial was a little bit nuanced because it did not meet its primary endpoint, but it had an embedded randomization based upon MRD status and they used a very sensitive test of measurable residual disease. They used a commercial assay by Invivoscribe that could look at the presence of a FLT3/ITD in the level of 10 to the minus 5th or 10 to the minus 6th. And if you were MRD-negative and you went through a transplant, you didn't seem to get an advantage versus not. That was of maintenance with gilteritinib, I'll just sort of put that on there. But it's telling us more about who should get a transplant and who shouldn't and who should get maintenance after transplant and who shouldn't.  A really compelling study a year ago from I don't know what to call the British group now, we used to call them the MRC and then the NCRI. I'm not quite sure what to call their studies at the moment. But Dr. Jad Othman did a retrospective study a year ago that looked at patients who had NPM1 mutation, the most common mutation AML, and looked to see if you were MRD positive or MRD negative, what the impact of a transplant was. And if you're MRD negative there was not an advantage of a transplant, whereas if you're MRD positive there was. And when they stratified that by having a FLT3 mutation that cracked. If you had a FLT3 mutation at diagnosis but your NPM1 was negative in remission, it was hard to show an advantage of a transplant. So I think we're getting much more discriminating about who should or should not get a transplant by MRD testing for NPM1 and that includes the patients who have a concomitant FLT3 mutation. And we're really trying to learn more and more. Do we really need to be doing transplants in those who are MRD-negative? If you have adverse risk genetics and you're MRD-negative, I'll really need good data to tell me not to do a transplant, but I suspect bit by bit, we'll get that data. And we're looking to see if that's really the case there, too. So measurable residual disease testing is helping us discriminate, but there is still a core role of allogeneic transplant. And to reassure you, compared to, I think your allotransplant days were some time ago if I'm right. Dr. John Sweetenham: Yes. Dr. James Foran: Yeah. Well, compared to when you were doing transplants, they're better now and better for patients now. And we get people through graft versus host disease better, and we prevent it better. Dr. John Sweetenham: That's a great answer, James. Thanks for that. It really does help to put it in context, and I think it also leads us on very nicely into what's going to be my final question for you today and perhaps the trickiest, in a way. I think that everything you've told us today really emphasizes the fact that the complexity of AML treatment has increased, primarily because of an improved understanding of the molecular landscape of the disease. And it's a complicated area now. So do you have any thoughts on what type of clinical environment patients with AML should be evaluated and treated in in 2025? Dr. James Foran: Yeah, I want to give you a kind of a cautious answer to that because, you know, I'm a leukemia doctor. I work at a leukemia center and it's what we focus on. And we really pride ourselves on our outcomes and our diagnostics and our clinical trials and so on. I am very aware that the very best oncologists in America work in private practice and work in community practice or in networks, not necessarily at an academic site. And I also know they have a much harder job than I have. They have to know lung cancer, which is molecularly as complicated now as leukemia, and they have to know about breast cancer and things that I don't even know how to spell anymore. So it's not a question of competence or knowledge. It's a question of infrastructure. I'll also put a little caveat saying that I have been taught by Rich Stone at Dana-Farber, where I did a fellowship a long time ago, and believe Rich is right, that I see different patients than the community oncologists see with AML, they're seeing different people. But with that caveat, I think the first thing is you really want to make sure you've got access to excellence, specialized hematopathology, that you can get expedited cytogenetics and NGS testing results back. There was a new drug, approved just a few months ago, actually, for relapsed AML with a KMT2A rearrangement, revumenib. We didn't talk about the menin inhibitors. I'll mention them in just a second. That's a huge area of expansion and growth for us. But they're not found on NGS platforms. And normal cytogenetics might miss a KMT2A-rearrangement. And we're actually going back to FISH panels, believe it or not, on AML, to try to identify who has a KMT2A-rearrangement. And so you really want to make sure you can access the diagnostic platforms for that.  I think the National Referral Labs do an excellent job. Not always a really fast job, but an excellent job. At my institution, I get NGS results back within three days or four days. We just have an expedited platform. Not everybody has that. So that's the key, is you have to be able to make the diagnosis, trust the pathologist, get expedited results. And then it's the question of trying to access the targeted medications because a lot of them are not carried in hospital on formulary or take time to go through an insurance approval process. So that's its own little headache, getting venetoclax, getting gilteritinib, getting an IDH1 inhibitor in first line, if that's what you're going for. And so I think that requires some infrastructure. We have case managers and nurses who really expedite that and help us with it, but that's a lot of work. The other piece of the puzzle is that we're still with AML in the first month and maybe even the second month. We make everybody worse before we make them better. And you have to have really good blood bank support. I can give an outpatient platelet transfusion or red cell transfusion seven days a week. We're just built for that. That's harder to do if you're in a community hospital and you have to be collaborating with a local blood bank. And that's not always dead easy for somebody in practice. So with those caveats, I do find that my colleagues in community practice do a really good job making the diagnosis, starting people on therapy, asking for help. I think the real thing is to be able to have a regional leukemia center that you can collaborate with, connect with, text, call to make sure that you're finding the right patients who need the next level of diagnostics, clinical trial, transplant consults, to really get the best results.  There was some data at ASH a couple of years ago that looked at – the American Society of Hematology and ASCOs had similar reports – that looked at how do we do in academic centers versus community practice for keeping people on therapy. And on average, people were more likely to get six cycles of therapy instead of three cycles of therapy with azacitidine venetoclax at an academic center. Now, maybe it's different patients and maybe they had different cytogenetics and so on, but I think you have to be patient, I think you have to collaborate. But you can treat those patients in the community as long as you've got the infrastructure in place. And we've learned with virtual medicine, with Zoom and other platforms that we can deliver virtual care more effectively with the pandemic and beyond. So I think we're trying to offer virtual consults or virtual support for patients so they can stay in their home, stay in their community, stay with their oncologists, but still get access to excellent diagnostics and supportive care and transplant consults, and so on. I hope that's a reasonable answer to that question. It's a bit of a nuanced answer, which is, I think there's an important role of a leukemia center, and I think there's a really fundamental role of keeping somebody in the community they live in, and how we collaborate is the key to that. And we've spent a lot of time and effort working with the oncologists in our community to try to accomplish that.  John, I want to say two other things. I didn't mention in the molecular platforms that NPM1 mutations, we can now target those on clinical trials with menin inhibitors. We know that NPM1 signals through the Hoxa9/Meis1 pathway. We know that similar pathways are important in KMT2A rearrangements. We know that there are some other rare leukemias like those with NUP98 rearrangement. We can target those with menin inhibitors. The first menin inhibitor, revuminib, was approved by the FDA for KMT2A. We have others going to the FDA later this year for NPM1. There are now pivotal trials and advanced expanded phase 1/2 studies that are showing 30% response rates. And we're looking to see can we add those into the first-line therapy. So, we're finding more targets.  I'll say one last thing about molecular medicine. I know I'm a little off topic here, but I always told patients that getting AML was kind of like being struck by lightning. It's not something you did. Now, obviously, there are risk factors for AML, smoking or obesity or certain farm environments, or radioactive exposures and so on. But bit by bit, we're starting to learn about who's predisposed to AML genetically. We've identified really just in the last five or eight years that DDX41 mutations can be germline half the time. And you always think germline mutations are going to cause AML in a younger patient, but the median age is 60 to 70 just like other AMLs. They actually might do pretty well once they get AML. We've reported that in several papers. And so we're trying to understand who that has a RUNX1 mutation needs germline testing, who with a DDX41 needs germline testing. And we're trying to actually come up with a cleaner pathway for germline testing in patients to really understand predisposition, to help with donor selection, to help with family counseling. So I think those are other areas where a leukemia center can contribute for somebody in who's community practice to understand genomic or genetic complexity in these patients. And we're starting to develop the databases that support that. Dr. John Sweetenham: Yeah, great. Thanks, James. I loved your answer about the clinical environment too. And I know from a patient-centric perspective that I know that patients would certainly appreciate the fact that we're in a situation now where the folks taking care of them will make every effort to keep them close to home if they possibly can.  I want to thank you, James, for an incredible review of a very complex subject and I think you did a great job. I think we all will have learned a lot. And thanks again for being willing to share your insights with us today on the ASCO Daily News Podcast. Dr. James Foran: John, it's my pleasure. And as you know, I'll do anything for a latte, so no problem at all. Dr. John Sweetenham: Okay. I owe you one, so thank you for that.  And thank you to our listeners for your time today. You'll find links to the studies we've discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. John Sweetenham  Dr. James Foran Follow ASCO on social media: @ASCO on Twitter ASCO on Bluesky ASCO on Facebook  ASCO on LinkedIn  Disclosures:    Dr. John Sweetenham:    No relationships to disclose Dr. James Foran: Stock and Other Ownership Interests: Aurinia Pharmaceuticals Consulting or Advisory Role: Peerview, CTI BioPharma Corp, Remix Therapeutics, Cardinal Health, Medscape, Syndax, Autolus Therapeutics Research Funding (Inst.): Chordia Therapeutics, Abbvie, Actinium Pharmaceuticals, Kura Oncology, Sellas Life Sciences, Novartis, Roivant, Celgene/Bristol-Myers Squibb, Astellas Pharma, SERVIER Travel, Accommodations, Expenses: Peerview

Join guest host Dr. Chrisna Perry and renowned multilingual learner expert Dr. Jim Cummins for an insightful episode of the Leading Voices in Literacy podcast. Together, they explore practical strategies educators can use to create a supportive, language-rich learning environment where multilingual learners thrive and reach their full academic potential. Don't miss this special episode packed with valuable tips and actionable advice that every literacy educator can bring to their classroom!Visit Savvas.com/Literacy today to learn more about our high-quality PreK-12 literacy solutions for your school district. To keep the conversation going follow us @SavvasLearning on Instagram, Facebook, X, Youtube, or Linkedin. Visit Savvas.com today to learn more about our award-winning K-12 programs and to request curriculum samples for your school or district.

(c) WDR 2025 Von WDR 5.

Außerdem: Sollten Männer den Führerschein später bekommen als Frauen? (10:13) // Mehr spannende Themen wissenschaftlich eingeordnet findet Ihr hier: www.quarks.de // Habt Ihr Feedback, Anregungen oder Fragen, die wir wissenschaftlich einordnen sollen? Dann meldet Euch über Whatsapp oder Signal unter 0162 344 86 48 oder per Mail: quarksdaily@wdr.de. Von Sebastian Sonntag.

In this episode of the Epigenetics Podcast, we talked with Yadira Soto-Feliciano from MIT about her work on the Menin-MLL complex and the effect of small molecules on its stability in leukemia. We explore the pivotal moments that led her to cancer biology during her graduate studies, where her work included ground-breaking research on the role of the plant homeodomain Finger protein-6 (PHF-6) in leukemia. This work bridged the realms of chromatin accessibility, transcription factors, and cancer cell lineage, providing critical evidence for the concept of lineage plasticity in cancer biology—a topic that has gained significant traction in recent years. Dr. Soto-Feliciano discusses how advances in techniques like CRISPR and ChIP-sequencing have shaped her research, enabling deeper insights into the mechanisms underlying cancer cell identity. As our discussion transitions, Dr. Soto-Feliciano shares her experience in David Allis's lab, illustrating how the collaboration across diverse scientific disciplines enhanced her understanding of chromatin biology and generated significant insights into the mechanics of epigenetic regulation. Highlighting a recent 2023 publication, we unpack her findings related to the conserved molecular switch between MLL1 and MLL3 complexes. These discoveries revealed how the application of small-molecule inhibitors of the menin-MLL interaction can alter gene expression and affect leukemia cells' responses to treatments. We also touch on the operational dynamics within her lab at MIT, established during challenging times marked by the pandemic. Yadira is dedicated to fostering a collaborative and respectful environment among her team, comprised of PhD candidates and research technicians, all sharing a commitment to unraveling the complexities of chromatin regulation. She emphasizes the significance of understanding chromatin scaffold proteins and their role in regulating gene expression and genome organization.   References Soto-Feliciano, Y. M., Bartlebaugh, J. M. E., Liu, Y., Sánchez-Rivera, F. J., Bhutkar, A., Weintraub, A. S., Buenrostro, J. D., Cheng, C. S., Regev, A., Jacks, T. E., Young, R. A., & Hemann, M. T. (2017). PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Genes & development, 31(10), 973–989. https://doi.org/10.1101/gad.295857.117 Soto-Feliciano, Y. M., Sánchez-Rivera, F. J., Perner, F., Barrows, D. W., Kastenhuber, E. R., Ho, Y. J., Carroll, T., Xiong, Y., Anand, D., Soshnev, A. A., Gates, L., Beytagh, M. C., Cheon, D., Gu, S., Liu, X. S., Krivtsov, A. V., Meneses, M., de Stanchina, E., Stone, R. M., Armstrong, S. A., … Allis, C. D. (2023). A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition. Cancer discovery, 13(1), 146–169. https://doi.org/10.1158/2159-8290.CD-22-0416 Zhu, C., Soto-Feliciano, Y. M., Morris, J. P., Huang, C. H., Koche, R. P., Ho, Y. J., Banito, A., Chen, C. W., Shroff, A., Tian, S., Livshits, G., Chen, C. C., Fennell, M., Armstrong, S. A., Allis, C. D., Tschaharganeh, D. F., & Lowe, S. W. (2023). MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer. eLife, 12, e80854. https://doi.org/10.7554/eLife.80854   Related Episodes MLL Proteins in Mixed-Lineage Leukemia (Yali Dou) Targeting COMPASS to Cure Childhood Leukemia (Ali Shilatifard)   Contact Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

In this episode of the New England Lacrosse Journal's 'Chasing the Goal' podcast, host Kyle Devitte interviews Deemer Class, co-founder of First Class Lacrosse and former pro and Duke lacrosse player. They discuss Deemer's journey from youth sports to playing at a Division I powerhouse like Duke, the rigorous training that shaped his career, and the transition into professional lacrosse with MLL and PLL. Deemer shares insights into First Class Lacrosse, emphasizing the importance of intentional training, personalized coaching, and maintaining a love for the game. The conversation also touches on the evolving culture of lacrosse, the scrutiny of elite programs, and the valuable experiences at the Division II and III levels.   Topics 00:40 Deemer Class: Early Life and Lacrosse Journey 03:08 College Experience at Duke 04:58 Transition to Professional Lacrosse 07:18 Founding First Class Lacrosse 09:25 Reflections and Evolution of First Class Lacrosse 13:14 Lacrosse Culture and Training Philosophy 20:22 Developing Elite Training Events 29:26 Engaging Youth Lacrosse Coaches 30:33 The Importance of Speed and Reps 31:37 Personalizing Coaching Approaches 32:32 Challenges of Modern Coaching 36:15 Gamifying Lacrosse Drills 38:54 The Reality of College Lacrosse 47:48 Balancing Expectations and Reality 52:56 What's Next for First Class Lacrosse?

In dieser Folge des ERCM Medizin Podcasts ist Prof. Dr. Dr. Torsten Haferlach, mein Gast, einer der führenden Hämatoonkologen und Leukämie-Spezialisten Deutschlands, sowie ein Experte für Künstliche Intelligenz in der Medizin. Prof. Haferlach ist Mitgründer des Münchner Leukämielabors (MLL), das in den letzten 20 Jahren zu einem der führenden Institute im Bereich hämatologische Diagnostik avancierte. Die zunehmende Digitalisierung bringt massive Datenmengen mit sich – insbesondere in der Medizin. Skalierbare KI-Systeme bieten enorme Chancen, die Gesundheitsversorgung nachhaltig zu verbessern. Was vor einigen Jahren wie eine Zukunftsvision schien, ist in vielen Bereichen heute Realität. Insbesondere im Bereich der Onkologie führt die Kombination aus medizinischer Bildanalyse und KI-gestützter Diagnostik zu einer beispiellosen Präzision und Geschwindigkeit in der Diagnosestellung. Gemeinsam sprechen wir darüber, wie verantwortungsvoll eingesetzte KI zu einer patientenzentrierten, individuellen Versorgung der Zukunft beitragen kann und wie die „digitale Patienten-Reise“ unser Gesundheitssystem verändert. "Der ERCM Medizin Podcast" Social & Webseite Instagram: https://www.instagram.com/ercm.podcast/ TikTok: https://www.tiktok.com/@ercm.podcast?lang=de-DE X (Twitter): https://twitter.com/ERCMPodcast Webseite: www.erc-munich.com Kontakt: podcast@erc-munich.com Prof. Dr. Dr. Torsten Haferlach Webseite: https://www.mll.com/ LinkedIn: https://www.linkedin.com/company/mll-muenchner-leukaemielabor/ Facebook: https://www.facebook.com/muenchnerleukaemielabor/ Instagram: https://www.instagram.com/muenchnerleukaemielabor/ Zeitangaben 00:00 – Einführung und Vorstellung von Prof. Dr. Dr. Haferlach 00:46 – Karriereweg und besondere Interessen von Prof. Haferlach 03:19 – Fortschritte in der Diagnostik 05:38 – Einsatz von KI in der Diagnostik 07:42 – KI-Anfänge im Münchner Leukämielabor 11:08 – KI in der medizinischen Bildanalyse 16:11 – KI und autonome Diagnostik 20:02 – Empathie vs. KI in der Medizin 26:01 – Deutsche Sicht auf Digitalisierung und KI 30:32 – Next Generation Sequencing erklärt 37:42 – Therapien und KI-gesteuerte Prognosen 43:18 – Genetische Prävention und Sequenzierung 52:16 – Digitale Infrastruktur und Cloud-Systeme 01:04:00 – KI-gestützte Befundschreibung 01:09:00 – Ausblick: KI-Zukunft in der Medizin Hashtags #ki #künstlicheintelligenz #leukämie #gesundheit #medizin #kiinmedizin #gesundheitswesen #Onkologie #MedizinPodcast #ercmpodcast

Außerdem: Warum machen wir noch so viel Müll - Sind wir zu bequem? (10:15) // Mehr spannende Themen wissenschaftlich eingeordnet findet Ihr hier: www.quarks.de // Habt Ihr Feedback, Anregungen oder Fragen, die wir wissenschaftlich einordnen sollen? Dann meldet Euch über Whatsapp oder Signal unter 0162 344 86 48 oder per Mail: quarksdaily@wdr.de. Von Sebastian Sonntag.

Mike is currently a Coach, Writer & Owner at Freak Strength and has been coaching for over 10 years. He has coached levels of athletes from NFL, MLB, NBA, MLL, MLS, WWE, Rugby League, Rugby Union and Olympic Gold medalists to pre-pubescent athletes.  He has also consulted for high caliber athletes and coaches worldwide. He has worked with NBA Champs, 10+ NFL Super bowl Champs, 10+ All-Pro/Pro-bowl selections. Mike also is the host of one of my favorite podcasts, The Mike and Brooker Show.    Follow Mike on Instagram   https://freakstrengthgym.com/  Check Out My Game Speed Course and Programs at www.multidirectionalpower.com  

On the latest episode of the Grateful And Full Of Greatness Podcast, host Mark Glicini interviews U.S. Lacrosse Hall of Famer, Pro Lacrosse Hall of Famer and NLL Hall of Famer Casey Powell. While at Syracuse University, Casey was a four-time All-American and two-time National Player of the Year. He was selected to play on four United States National teams and was captain of Team USA in 2006, 2011 and again in 2015. He spent 11 seasons in the NLL and 13 in the MLL, winning MVP in both leagues and three MLL championships. Casey is also the owner and director of lacrosse education for CP Lacrosse which runs camps, clinics, and tournaments nationally. Along with his brothers, their brand Powell Lacrosse designs, manufactures, and sells the world's best lacrosse sticks. He is also the founder of SPEED Lacrosse™ and co-founder of The Casey Powell World Lacrosse Foundation which supports severely injured and sick lacrosse players. WHOOP OFFER: FREE BAND + FREE 1ST-MONTH SUBSCRIPTION: https://join.whoop.com/mgpp THORNE OFFER: 25% OFF ALL SUPPLEMENTS: https://www.thorne.com/u/markglicini Listen/Watch on YouTube: https://www.youtube.com/channel/UCZnNdml6HYHdQx48SwmZhWQ Visit Mark Glicini's Website: https://www.markglicini.com/

Hey Podtimists, This week David has a small mountain of games to talk about, including the new and wonderful Astrobot. Chase also played Astrobot but he also played Baten Kaitos. Finally, we took a deeper look at Digimon World 3. This one was suggested to us by listener MLL. Thanks MLL! --- Timestamps: (0:00) - Intro (1:24) - Some cool news! (2:46) - What David has been playing (2:56) - Hyper Lite Drifter (3:37) - Sekiro Shadows Die Twice (8:07) - Mario Wonder (9:41) - Lumines (13:59) - Astrobot (34:00) - What Chase has been playing (34:30) - Baten Kaitos (52:04) - Chase's Podtimistic thing of the week (55:29) - David's Podtimistic thing of the week (57:57) - Good Games! Featuring Digimon World 3 (1:23:08) - Outro --- Games mentioned: Hyper Lite Drifter Mario Wonder Lumines Astrobot Baten Kaitos Sekiro Shadows Die Twice Digimon World 3

This episode of Literacy Talks delves into the unique strengths and needs of multilingual learners (MLLs). Hosts Stacy Hurst, Donell Pons, and Lindsay Kemeny share valuable insights and practical strategies for effectively teaching phonemic awareness, phonics, vocabulary, and reading comprehension to MLLs. They emphasize the importance of honoring students' home languages, building on their existing linguistic knowledge, and creating a welcoming, celebratory environment that empowers all students. Listeners will appreciate the cognitive advantages of learning multiple languages and come away with concrete ideas for supporting the literacy development of this rapidly growing student population. Whether you're a classroom teacher, literacy specialist, or administrator, this episode offers essential guidance for ensuring multilingual learners thrive.Show NotesLiteracy Leaders:Stanislas DehaeneResources:What's the Difference Between ESL, EFL, ESOL, ELL, MLL, and ESP?—Reading Horizons BlogEnglish Learners in Public Schools—NCESWhat Languages Do We Speak in the United States?—US Census BureauMylanguages.orgColorin ColoradoAcadienceWordsmythStanislas Dehaene Summit 2024 Virtual KeynoteThe Syntax ProjectTerms:ELL: English Language LearnersESL: English as a Second LanguageESOL: English for Speakers of Other LanguagesML/MLL: Multilingual LearnersBIC: Basic Interpersonal CommunicationText engineering: a strategy that modifies grade-level texts to help students understand them better. The goal is to make the text more accessible without simplifying it or lowering its complexity.Download the Reading Horizons Discovery Product Guide.Access past show notes.Read the transcripts.

Außerdem: Trauer - So kannst Du gut damit umgehen (08:00) // Mehr spannende Themen wissenschaftlich eingeordnet findet Ihr hier: www.quarks.de // Habt Ihr Feedback, Anregungen oder Fragen, die wir wissenschaftlich einordnen sollen? Dann meldet Euch über Whatsapp oder Signal unter 0162 344 86 48 oder per Mail: quarksdaily@wdr.de. Von Ina Plodroch.

In this episode of the Epigenetics Podcast, we talked with Johnathan Whetstine from Fox Chase Cancer Center about his work on how histone demethylases affect gene expression and cancer cell stability. The Interview start by discussing a pivotal paper from Jonathan's lab in 2010, where they identified a role for the KDM4A histone demethylase in replication timing and cell cycle progression. They elaborate on the discoveries made regarding the link between histone marks, replication timing, and gene expression control. Jonathan explains the impact of microRNAs on regulating KDM4A and how protein turnover rates can influence cellular responses to treatments like mTOR inhibitors. Further, they explore the causal relationship between histone marks and replication timing, demonstrating how alterations in epigenetic regulation can affect genome stability. Jonathan shares insights from his latest research on H3K9 methylation balance at the MLL-KM2A locus, elucidating how these epigenetic modifications regulate amplifications and rearrangements in cancer cells. The episode concludes with a discussion on the establishment of the Cancer Epigenetics Institute at Fox Chase Cancer Center, aiming to bridge academia and industry to accelerate translational research in cancer epigenetics.   References Black, J. C., Allen, A., Van Rechem, C., Forbes, E., Longworth, M., Tschöp, K., Rinehart, C., Quiton, J., Walsh, R., Smallwood, A., Dyson, N. J., & Whetstine, J. R. (2010). Conserved antagonism between JMJD2A/KDM4A and HP1γ during cell cycle progression. Molecular cell, 40(5), 736–748. https://doi.org/10.1016/j.molcel.2010.11.008 Mishra, S., Van Rechem, C., Pal, S., Clarke, T. L., Chakraborty, D., Mahan, S. D., Black, J. C., Murphy, S. E., Lawrence, M. S., Daniels, D. L., & Whetstine, J. R. (2018). Cross-talk between Lysine-Modifying Enzymes Controls Site-Specific DNA Amplifications. Cell, 174(4), 803–817.e16. https://doi.org/10.1016/j.cell.2018.06.018 Van Rechem, C., Ji, F., Chakraborty, D., Black, J. C., Sadreyev, R. I., & Whetstine, J. R. (2021). Collective regulation of chromatin modifications predicts replication timing during cell cycle. Cell reports, 37(1), 109799. https://doi.org/10.1016/j.celrep.2021.109799 Gray, Z. H., Chakraborty, D., Duttweiler, R. R., Alekbaeva, G. D., Murphy, S. E., Chetal, K., Ji, F., Ferman, B. I., Honer, M. A., Wang, Z., Myers, C., Sun, R., Kaniskan, H. Ü., Toma, M. M., Bondarenko, E. A., Santoro, J. N., Miranda, C., Dillingham, M. E., Tang, R., Gozani, O., … Whetstine, J. R. (2023). Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement. Cell, 186(21), 4528–4545.e18. https://doi.org/10.1016/j.cell.2023.09.009   Related Episodes The Impact of Chromatin Modifiers on Disease Development and Progression (Capucine van Rechem)   Contact Epigenetics Podcast on X Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Epigenetics Podcast on Threads Active Motif on X Active Motif on LinkedIn Email: podcast@activemotif.com

Vor 50 Jahren wurde das zu dem Zeitpunkt modernste AKW der Welt in Betrieb genommen: Das AKW Biblis. Heute ist davon nicht mehr viel übrig, außer hochradioaktiver Atommüll. Aktuell steht dieser in Zwischenlagern - wie zum Beispiel in Biblis. Die Genehmigung dafür läuft allerdings nur bis ins Jahr 2046. Was dann?

In dieser Folge beschäftigen wir uns mit einem Thema, das wir Menschen gerne ausblenden, frei nach dem Motto „Aus den Augen, aus dem Sinn“: Es geht um unseren Müll. Den schmeißen wir nämlich am liebsten Weg und vergessen dann ganz schnell, dass es ihn mal gab. Dabei ist Müll nie wirklich weg. Und das weiß mein Gast in dieser Folge aus erster Hand zu berichten, denn Oliver Schlaudt hat sich für sein neues Buch „Zugemüllt“ auf eine müllphilosophische Deutschlandreise begeben. Oliver ist Professor für Philosophie und Politische Ökonomie an der Hochschule für Gesellschaftsgestaltung in Koblenz. Und in seinem Buch zeigt er uns Orte, bei denen man ehrlich sein muss: Man bedauert, dass es diese Orte geben muss, weil wir Menschen so viel Müll verursachen. Warum er trotzdem irgendwie optimistisch in die Zukunft blickt, auch wenn man das nach dieser zugegeben etwas düsteren Reise nicht denken würde, das verrät er in dieser Folge. Alle Infos zum Buch: https://www.chbeck.de/schlaudt-philosophie-muells/product/36288722 Bei Oliver Schlaudt studieren könnt ihr an der Hochschule für Gesellschaftsgestaltung: https://hfgg.de/ Mehr Inhalte von Oliver Schlaudt findet ihr bei Instagram: https://www.instagram.com/hfgg_hochschule/

Researchers in fields as diverse as astronomy, chemistry, neuroscience, biotechnology and public health are now using AI tools to look for patterns in their data, write code, find and summarize existing scientific literature, and even design experiments. Someday, scientific discoveries might even be made entirely by AI.We sat down with two guests for a bird's eye view of how AI tools and approaches are boosting scientific discovery. Adam Klivans is a professor of computer science and the director of the Machine Learning Lab (MLL), which is a kind of umbrella organization for interdisciplinary AI research across the university. He also co-leads the Institute for Foundations of Machine Learning (IFML), which focuses on the fundamental theories behind AI. And Alex Dimakis is a professor of computer and electrical engineering. Along with Adam, he co-directs both the MLL and IFML and leads the new Center for Generative AI.Dig DeeperPeering in a Stellar Nursery, Texas Scientist MagazineHow New Machine Learning Techniques Could Improve MRI Scans, Amazon ScienceLululemon is experimenting with the first fabric made from recycled carbon emissions, Fast Company (this is the story referred to by Adam Klivans about Lanzatech turning carbon monoxide emissions into yoga pants to fight climate change)From Chatbots to Antibiotics, Texas Scientist MagazinePlastic-eating Enzyme Could Eliminate Billions of Tons of Landfill Waste, UT NewsBrain Activity Decoder Can Reveal Stories in People's Minds, Point of Discovery podcastAlzheimer's Drug Fermented With Help From AI and Bacteria Moves Closer to Reality, UT NewsAlphaFold, Wikipedia (the AI model from Deep Mind that Adam Klivans mentioned that has made great strides in predicting the shapes that proteins take)DataComp LM (UT's open access dataset for training large language models)Episode CreditsOur co-hosts are Marc Airhart, science writer and podcaster in the College of Natural Sciences and Casey Boyle, associate professor of rhetoric and director of UT's Digital Writing & Research Lab.Executive producers are Christine Sinatra and Dan Oppenheimer. Sound design and audio editing by Robert Scaramuccia. Theme music is by Aiolos Rue. Interviews are recorded at the Liberal Arts ITS recording studio.Elements of the cover image for this episode were generated using Midjourney and Photoshop's generative AI tools. About AI for the Rest of UsAI for the Rest of Us is a joint production of The University of Texas at Austin's College of Natural Sciences and College of Liberal Arts. This podcast is part of the University's Year of AI initiative. The opinions expressed in this podcast represent the views of the hosts and guests, and not of The University of Texas at Austin. You can listen via Apple Podcasts, Spotify, Amazon Podcasts, RSS, or anywhere you get your podcasts. You can also listen on the web at aifortherest.net. Have questions or comments? Contact: mairhart[AT]austin.utexas.edu

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2024 Congress including:Data from the prospective, single-center phase Ib/II study of FLAG-IDA plus venetoclax in newly diagnosed or relapsed/refractory AML Phase I/II study of oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with newly diagnosed and relapsed/refractory FLT3-mutant AMLA retrospective comparison of abbreviated course 7+7 vs standard HMA plus venetoclax doublet in older/unfit patients with newly diagnosed AML Multisite randomized trial of a collaborative palliative and oncology care model for patients with AML and myelodysplastic syndromes (MDS) receiving nonintensive therapyFinal 5-year results from the phase II pivotal cohort of olutasidenib for IDH1-mutated AML Post hoc analyses of outcomes in patients with AML and MDS-related changes who received oral azacitidine maintenance therapy in the phase III QUAZAR AML-001 studyFirst-in-human phase I/II of the menin-MLL inhibitor DSP-5336 in patients with R/R acute leukemia: updated results from the dose escalation phase A phase Ib study of the menin-KMT2A inhibitor bleximenib in combination with venetoclax and azacitidine in R/R AML with alterations in KMT2A or NPM1 Program faculty:Eunice S. Wang, MDChief, Leukemia and Benign Hematology ServiceProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkCourtney DiNardo, MD, MSCEProfessor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterHouston, TexasResources:To download the slides associated with this podcast discussion, please visit the program page:https://bit.ly/4bvJGij

One of the oldest sports known to man will be featured tonight on the Original Sports Podcast. Our guest is ultra successful Michael Rabil. Yes, that Michael Rabil of the Premiere Lacrosse League fame. He will talk about how he and his brother, Paul, have made Lacrosse a household sports name over the last several years and what the plan is going forward to continue the growth. We are excited to learn all about America's fastest growing sport. BSC intro:   Spontaneous Reactions:  Main Segment:   Talk about growing up and your involvement with sports?   Why Dartmouth?   You played football at Dartmouth, why not LAX?   Share with us your biggest obstacles you encountered with PLL thus far?   As an Ivy League school we know the education was off the charts at Dartmouth but how did it prepare you to build the PLL?   Were you ever close to purchasing the MLL  before  ultimately deciding to go forward with creating PLL? And how did the merger occur?   Talk about any interest you have outside of PLL?   What is your day to day like on a regular basis with PLL?   How have you created a fan friendly experience and what can someone expect when going to games?   Do you anticipate ever housing teams in the city they represent or is the rotating schedule part of the allure?   Share with us some of the marquee guys aside from your brother Paul who have been instrumental in the first few years of the league?    Where would you like to see the PLL at in the next 5 to 10 years?   Finally, what words of wisdom do you have for our listeners who maybe young, inspiring lacrosse players? T-Sizzle Fax   “The Dream” ?   Next Episode:    Michael “Chops” Mills @therealbigchops  Terry “T-sizzle” Young : Instagram and Twitter @1youngterry Michael “Coach Neubeiser” Neubeiser: Instagram and Twitter @coachneub Rashene “Real Deal” Hill: Facebook @RasheneHill and Instagram @miramaitamshene ===========================  CONNECT WITH US  ===========================  Check out our websites, social media and networks we are featured on:  https://www.podpage.com/originalsportspodcastwithmarkmaradei/  Like our Facebook page https://www.facebook.com/OSPwithMM Join the conversation on Twitter https://twitter.com/OSPwithMM Reach out to us on Snapchat at: OSPwithMM Follow us on Instagram pics https://www.instagram.com/originalsportspodcast                         Watch our Tik Tok at: OriginalSportsPodcast Subscribe to our YouTube channel: https://www.youtube.com/channel/UCVZuudj681oIAbnscyHBa0g?view_as=subscriber  Find us on: Let's Talk Sports Network, https://sidelinesportsnet.com/  and Elite Sports and Entertainment Network. Catch our Roku Show on Tuesday Nights from 9-10 pm  ===========================  Feel free to let us know if you have any comments or questions By emailing us at: OriginalSportsPodcast@gmail.com Voice intro: Steve Medley Intro and outro music provided by Charlie Hodgson Join us every week to Experience the “O” on the Original Sports Podcast!!!   @ClaudioReilsano @Topoffsports @SportsPodiumPodcast @TheMicDr @MarLovelace1 @100Sanford @coachmaradei @Letstalksports @TribuneSouth @BBALLBABE6 @NFLDraftEd @Key103Radio @1069THEEAGLE  @ShkBkMediaGrp @MunnseyTalks @JB_ThePROgram @ecwilson76 @LandersTalks @Mancinisports @GridironXtra @GridironGrubb @GridironZeroes @GridironGuru2 @OSPwithMM @thrillofsports @SmokeyHellNFL @jennacheryl @ShkBkMediaGrp @SteveB7SFG @CFBWeekly @ecwilson76 @LandersTalks @RadioJakeTaylor @tssjester @1youngterry @coachneub @MediaManning @ListenFrederick @ListenHubCity  @therealbigchops   

Oliver Schlaudt hat sich auf eine müllphilosophische Reise durch Deutschland begeben. Was er dabei über unseren Umgang mit Müll herausgefunden hat, darüber spricht er mit Jürgen Wiebicke. Von WDR 5.

On the latest episode of the Grateful And Full Of Greatness Podcast, host Mark Glicini interviews Kyle Sweeney, former pro lacrosse player in both the National Lacrosse League and Major League Lacrosse. Listeners will hear Kyle discuss how effort alone is insignificant without results, the importance of developing habits and a routine and how having a clear vision can help you achieve your professional and personal goals. Kyle also discusses his hall of fame lacrosse career and the trials he faced building Maverik into the lacrosse manufacturer it is today. To learn more about Kyle Sweeney, visit: https://www.theplayerstribune.com/articles/kyle-sweeney-lacrosse-retirement Kyle Sweeney is a graduate of Georgetown University and played 14 seasons professionally, winning four MLL Championships and two gold medals with Team USA. He was recently named a member of the National Lacrosse Hall of Fame and Professional Lacrosse Hall of Fame. He played for the Bridgeport/Philadelphia Barrage, Boston Cannons Washington/Chesapeake Bayhawks and New York Lizards in the MLL and Philadelphia Wings, Edmonton Rush and Buffalo Bandits in the NLL. WHOOP OFFER: FREE BAND + FREE 1ST-MONTH SUBSCRIPTION: https://join.whoop.com/mgpp THORNE OFFER: 25% OFF ALL SUPPLEMENTS: https://www.thorne.com/u/markglicini OTHER WAYS TO LISTEN AND WATCH Listen/Watch on Spotify: https://open.spotify.com/show/1Ruq1L8SNPyGmAqLdrVAVQ Listen on Apple Podcasts: https://podcasts.apple.com/us/podcast/grateful-and-full-of-greatness-with-mark-glicini/id1498665905?uo=4 Visit Mark Glicini's Website: https://www.markglicini.com/

Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence. Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting." "That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent." "There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal." #KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML KuraOncology.com Download the transcript here

Dr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence. Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting." "That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent." "There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal." #KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML KuraOncology.com Listen to the podcast here

We're taking just a little time off to allow room for some international moves and wrapping up of projects. But first, listen in for a BRAND NEW ANNOUNCEMENT about Brent's latest project... or if you already listened and just want to get on the mailing list, please sign up at www.DIESOL.org/book  In the meantime, enjoy a revisit to a few episodes that continue to provide value and can spark some ideas you forgot about over the last year. We're starting off with our January episode of 24 Tools for 2024 and a chance to look at some ways you can integrate interesting tools into your classes.  You can find the original show notes for this episode at www.DIESOL.org/96 

The manufacturing process is a carefully orchestrated system where each step is as important as the next. But oftentimes there is limited real-time inspection of parts, and defects are detected too late or missed. Enter Eigen Innovations, the Intel-supported AI system that allows workers to be more efficient and helps manufacturers avoid losing money on returns and recalls of defective products. In this episode, Eigen executive Jon Weiss discusses what's next at the intersection of manufacturing and technology, including the crucial role Intel will play in an essential industry that drives the global economy. Learn more about how Intel is leading the charge in the AI Revolution at intel.com/AIeverywhereSee omnystudio.com/listener for privacy information.

Das sind die Themen von Flo und Lisa am 30.05.2024: (00:00:00) Falsche Wahlzettel: Wie Menschen in Dresden aufgefallen ist, dass sie falsche Wahlzettel für die Europawahl bekommen haben. (00:01:38) Sponsoren im Fußball: Warum viele gerade über Rheinmetall und den BVB diskutieren und welche anderen fragwürdigen Sponsoren es gibt. Für die Europameisterschaft gibt es einen neuen Podcast „Das EM Update“ – täglich ab dem 13. Juni http://www.wdr.de/k/podcast-das-em-update. (00:09:18) Fliegende Müllsäcke: Warum Nordkorea mit Müll gefüllte Ballons über die Grenze nach Südkorea schickt. (00:11:40) Habeck im Interview: Wie Habeck zum Krieg in Nahost steht, was er von der AfD hält und wieso Wirtschaftswachstum und Klimaschutz für ihn gut zusammenpassen – und für wen er bei der Fußball EM ist. Das ganze Interview gibt es hier: http://www.wdr.de/k/habeck-interview (00:20:21) Tag der Nachbarn: Was sind eure weirdesten Nachbarschaftsgeschichten und wem wollt ihr mal „Danke“ sagen fürs Pakete annehmen? Schickt uns eine Sprachnachricht an 0151 15071635! Von 0630.

On the latest episode of the Grateful And Full Of Greatness Podcast, host Mark Glicini interviews Greg Gurenlian, former pro lacrosse player in both the Premier Lacrosse League and Major League Lacrosse. Listeners will hear Greg discuss why discipline is so important in both lacrosse and every day life, how he went from a first-year player who wanted to quit in high school to a gold medalist and MLL champion and how he perfected his craft as one of the most dominant faceoff athletes in pro lacrosse history. To learn more about Greg Gurenlian, visit: https://www.thefaceoffacademy.com/staff Greg Gurenlian is a graduate of Penn State University and played 14 seasons professionally, winning an MLL MVP and an MLL Championship in 2015 with the New York Lizards, setting the career record for faceoff wins and groundballs and winning a gold medal with Team USA in 2018. Gurnelian was a member of the Redwoods Lacrosse Club in the innaugural PLL season and helped lead the team to a 2019 PLL Championship appearance. Greg currently coaches the next generation of faceoff athletes as a founder and coach with the Faceoff Academy. WHOOP OFFER: FREE BAND + FREE 1ST-MONTH SUBSCRIPTION: https://join.whoop.com/mgpp THORNE OFFER: 25% OFF ALL SUPPLEMENTS: https://www.thorne.com/u/markglicini

Zwischen nervig, nützlich und gefährlich - Unser Leben mit dem Staub ; Geisternetze - tödlicher Müll im Meer ; Die wahren Kosten der Lebensmittel ; Wut - Warum durchatmen besser ist als Dampf ablassen ; Wie sinnvoll ist ein Handyverbot in der Schule? ; Weinen - Ist es gut für Körper und Seele? ; Wie Schimmelpilzkäse bunt wird ; Dimension Ralph: Synästhesie ; Moderation: Stephanie Klaus. Von WDR 5.

AI has the potential to revolutionize how we support multilingual learners. By leveraging AI-powered tools, it is hoped that educators can create inclusive and effective learning environments that foster linguistic and cultural diversity and harness Artificial Intelligence to support MLL's. On tonight's panel:Atala Andratis @AMASparkleKimiko Shibata @ESL_fairyDr. Michelle Shory @michelleshory

·       Nascentmc.com for medical writing assistance for your company.Visit nascentmc.com/podcast for full show notes Cilta-cel for Myeloma: The FDA approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for adults with relapsed or refractory multiple myeloma who have tried at least one prior therapy including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. This CAR T-cell therapy, initially approved in 2022, was confirmed effective in the phase 3 CARTITUDE-4 study, showing significant reduction in disease progression or death risk by 59% compared to standard care. Enhertu for HER2-positive Solid Tumors: Fam-trastuzumab deruxtecan-nxki (Enhertu) received FDA approval for treating unresectable or metastatic HER2-positive solid tumors in adults who have had previous systemic treatment and lack satisfactory alternative options. This therapy, a conjugate of an anti-HER2 antibody and a cytotoxic drug, was first approved in 2019 and targets HER2-expressing cancer cells to potentially minimize damage to normal tissues. Fanapt for Bipolar: Iloperidone (Fanapt) has been approved for the acute treatment of manic or mixed episodes in adults with bipolar I disorder. Previously approved for schizophrenia, iloperidone targets neurotransmitters like dopamine and serotonin. It demonstrated efficacy in a pivotal trial, showing significant improvement on the Young Mania Rating Scale. Zevtera for Multiple Bacterial Infections: Ceftobiprole medocaril sodium (Zevtera) was approved for treating adults with Staphylococcus aureus bloodstream infections, right-sided infective endocarditis, and acute bacterial skin and skin structure infections. Also approved for pediatric community-acquired bacterial pneumonia, ceftobiprole is a broad-spectrum cephalosporin that combats various bacteria including MRSA. TriClip for Tricuspid Regurgitation: The FDA approved the TriClip™ transcatheter edge-to-edge repair system for treating tricuspid regurgitation. This minimally invasive option clips the tricuspid valve leaflets to improve blood flow and prevent the need for surgery. The TRILUMINATE Pivotal trial showed significant improvements in TR severity and quality of life with a good safety profile. Revumenib for Acute Leukemia: The FDA granted priority review to revumenib (SNDX-5613) for treating adult and pediatric patients with relapsed or refractory acute leukemia with KMT2A rearrangements. As a new therapeutic agent, revumenib inhibits the menin-MLL protein interaction crucial in leukemic transformation. Early trial results show promising remission rates, with a PDUFA action date scheduled for September 26, 2024.  

On the latest episode of the Grateful And Full Of Greatness Podcast, host Mark Glicini interviews Gary Gait, current Syracuse men's lacrosse head coach and former pro lacrosse player in both the National Lacrosse League and Major League Lacrosse. Listeners will hear about creating championship standards, how he and his brother Paul Gait used their compeitive drive to fule their success on the lacrosse field, and taking ownership of one's career. To learn more about Gary Gait, visit: https://cuse.com/sports/mens-lacrosse/roster/coaches/gary-gait/5737 Gary Gait is a graduate of Syracuse University, where he and his brother Paul Gait led Syracuse's most dominant stretch in program history, losing just one game in three seasons from 1988-90 and winning three NCAA championships. At the professional level as a player, Gait has won three NLL titles (1991, 1994, 1995), three MLL titles, (2001, 2002, 2005), three Mann Cups (1991, 1997, 1999), the Heritage Cup (2004) and the ILF World Championship (2006). WHOOP OFFER: FREE BAND + FREE 1ST-MONTH SUBSCRIPTION: https://join.whoop.com/mgpp THORNE OFFER: 25% OFF ALL SUPPLEMENTS: https://www.thorne.com/u/markglicini OTHER WAYS TO LISTEN AND WATCHListen/Watch on Spotify: https://open.spotify.com/show/1Ruq1L8SNPyGmAqLdrVAVQ Listen on Apple Podcasts: https://podcasts.apple.com/us/podcast/grateful-and-full-of-greatness-with-mark-glicini/id1498665905?uo=4Visit Mark Glicini's Website: https://www.markglicini.com/

In this episode of the Digital Learning Today Podcast, Jeff welcomes Dr Jayne Lammers, Director of Learning Design at Edmentum on the podcast to discuss how your school district can begin using Artificial Intelligence to support staff, students, and the community. If you are a new listener to TeacherCast, we would love to hear from you.  Please visit our Contact Page and let us know how we can help you today! In This Episode … How do we define the term “Generative AI”? Do we need to be worried about Privacy Agreements when using applications with AI? What questions should Tech Directors be asking EdTech Companies about their AI features? How will school districts be notified of changes in AI in apps? What switches will the district have to control AI features? What types of language should be in an AI policy? Introducing AI to staff at a group meeting? Start with a problem that is broad and discuss how AI can help solve it. Language Support for MLL students and families (claude.ai) Will AI ever replace teachers in the classroom? How to teach AI to students as a “thought buddy” The importance of sharing and reflecting after using AI so others can learn about it together AI Applications Mentioned on the Podcast School.ai MagicSchool.ai Claude.ai Website Links Mentioned on the Podcast about AI https://www.commonsense.org/education/digital-citizenship/lesson/what-is-ai Articles Referenced https://www.edmentum.com/articles/generative-ai-in-education-experiments Follow Our Podcast And Subscribe View All Episodes Apple Podcasts Google Podcasts Stitcher Radio Follow Our Host Jeff Bradbury | @JeffBradbury TeacherCast | @TeacherCast About our Guest: Dr. Lammers began her education career as a middle and high school literacy teacher and found a passion for supporting teachers in meeting the needs of striving readers. She earned her Ph.D. in Curriculum & Instruction at Arizona State University and spent 15 years in higher education, preparing teachers for the challenges of today's classrooms. Her research explored the intersection of students' interests and technology's affordances, aiming to make literacy instruction more meaningful and impactful. Now, as the Director of Learning Design at Edmentum, Dr. Lammers helps ensure that Edmentum's products designed to accelerate learning leverage research-based best practices and consider the realities of teachers' work and students' needs. About EdMentum

Populist:innen kann man nicht auf argumentativer Ebene schlagen, sondern nur auf der kommunikativen, meint unser Gast. Warum der Wohnungsmangel in Deutschland Frauen stärker trifft als Männer, besprechen wir am Küchentisch. Und: die Zukunft des Streiks. Von WDR 5.

Redeem your EUR 75 bonus at Splint Invest with code Dali24: https://splintinvest.onelink.me/ZGYb/swppod Timestamps: 3:50 - Deciding to acquire TwicPics 16:30 - The smallpdf fuckup 20:37 - Integrating two cultures  26:20 - When to start thinking about acquisitions 32:50 - Resorting to investment banks About Roger Dudler & Dennis Just: On August 29th the Swisspreneur community got together for the third edition of its annual Zurich Scaleup Cruise, sponsored by Swisscom Ventures, SIX, UBS, MLL and Emerald Ventures. With about 130 founders and investors, there were plenty of people to connect with on the Panta Rhei ship on that late August evening, while you enjoyed a flying dinner and the view of Lake Zurich. Many of the participants were veteran Swisspreneur cruisers: it was their 3rd time attending!  The highlight of the evening was the panel discussion with Roger Dudler, co-founder and CEO at Frontify, and Dennis Just, partner at 3VC and former CEO at smallpdf, on buying or building to scale.  Since there are as many founder journeys as there are founders, the audience wasn't surprised to hear that different things led Roger and Dennis to go forward with their respective acquisitions: for Frontify, acquiring TwicPics came as a natural result of their company growth, whereas for smallpdf the acquisition of PDFtools was the result of a neck-to-neck bidding war that they decided to engage in so as to stop their partner from being acquired by an American buyer who would raise PDFtool's pricing.  Smallpdf acquired PDFtools in 2022 for 30M (which is 10M less than the seller would have gotten from the American bidder, and that certainly speaks in smallpdf's favor), half of which was paid in cash and half financed by a loan from Swiss banks — such are the benefits of being a bootstrapped, profitable company! Frontify, on the other hand, acquired Twicpics in 2023 for an undisclosed amount.  With the deal closed, came the harder part: integration. Dennis quickly realized that smallpdf and PDFtools were not 100% aligned values-wise, since the acquirer's growth ambitions were much higher than the acquired's, so it was necessary to bring PDFtools “up to speed”. Eventually, Dennis and the smallpdf team decided to integrate the two companies regarding culture (same salaries, growth plans, etc) but not when it came to corporate structure, because PDFtool's customer base was rather enterprise-heavy, whereas smallpdf was more B2C-focused. Their branding and go-to-market strategy thus remained separate.  Frontify is going through a similar process, even setting up a specific team to manage the integration, which meets weekly with management and follows a very clear plan.  When answering questions from the audience, Dennis noted that companies smaller than 50-100 employees should not think about acquiring other businesses, since you need 3-4 people fully dedicated to the matter anyway, as well as the proper processes and structures set up. And although acquisition becomes a bit of an expectation for companies at a series C round level and beyond, Roger warned founders against taking up offers from the sellers who come knocking around this stage: it is much better to build your M&A muscle proactively and wait for the right time to seek out companies yourself. Even after the panel discussion finished and the attendants ate the last of their dessert, there were people who simply could not stop networking (can you blame them?), so the party continued on land at the Metropol. It was a fantastically successful evening overall and we can't wait for next year's edition!

In this episode of the Epigenetics Podcast, we talked with Yali Dou from Keck School of Medicine of USC about her work on MLL Proteins in Mixed-Lineage Leukemia. To start off this Interview Yali describes her early work on MLL1 and its function in transcription, particularly its involvement in histone modification. She explains her successful purification of the MLL complex and the discovery of MOF as one of the proteins involved. Next, the interview focuses on her work in reconstituting the MLL core complex and the insights gained from this process. She shares her experience of reconstituting the MLL complex and discusses her focus on the crosstalk of H3K4 and H3K79 methylation, regulated by H2BK34 ubiquitination. The podcast then delves into the therapeutic potential of MLL1, leading to the discovery of a small molecule inhibitor. Finally, we talk about the importance of the protein WDR5 in the assembly of MLL complexes and how targeting the WDR5-ML interaction can inhibit MLL activity.   References Dou, Y., Milne, T., Ruthenburg, A. et al. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol 13, 713–719 (2006). https://doi.org/10.1038/nsmb1128 Wu, L., Zee, B. M., Wang, Y., Garcia, B. A., & Dou, Y. (2011). The RING Finger Protein MSL2 in the MOF Complex Is an E3 Ubiquitin Ligase for H2B K34 and Is Involved in Crosstalk with H3 K4 and K79 Methylation. Molecular Cell, 43(1), 132–144. https://doi.org/10.1016/j.molcel.2011.05.015 Cao, F., Townsend, E. C., Karatas, H., Xu, J., Li, L., Lee, S., Liu, L., Chen, Y., Ouillette, P., Zhu, J., Hess, J. L., Atadja, P., Lei, M., Qin, Z. S., Malek, S., Wang, S., & Dou, Y. (2014). Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia. Molecular Cell, 53(2), 247–261. https://doi.org/10.1016/j.molcel.2013.12.001 Park, S.H., Ayoub, A., Lee, YT. et al. Cryo-EM structure of the human MLL1 core complex bound to the nucleosome. Nat Commun 10, 5540 (2019). https://doi.org/10.1038/s41467-019-13550-2   Related Episodes Dosage Compensation in Drosophila (Asifa Akhtar) Targeting COMPASS to Cure Childhood Leukemia (Ali Shilatifard)   Contact Epigenetics Podcast on X Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Epigenetics Podcast on Threads Active Motif on X Active Motif on LinkedIn Email: podcast@activemotif.com

Dan Soviero talks about how he decided to drop out of college and become an entrepreneur, how he used equity crowdfunding to raise money for his business, and much more.IN THIS EPISODE, YOU'LL LEARN:00:00 - Intro02:38 - Things to consider when deciding to drop out of college. 13:37 - What the NLL is and how it's different from the MLL and PLL, which have now merged.19:06 - How to form a relationship with the NLL and other professional leagues to become the official ball.26:27 - What it means from a business perspective to be the exclusive provider or official ball of a sports league and what the strategy and goal are with a relationship like this.26:27 - What Dan's long-term goal with Signature Lacrosse is. 32:42 - What the benefits of hiring athletes are.33:06 - How Signature Lacrosse competes in a competitive industry and what makes them different from other lacrosse equipment companies.33:48 - Why choosing to do equity crowdfunding is a good source for raising capital.47:21 - The habits or principles Dan have incorporated into his life that have lead to his success.And much, much more!*Disclaimer: Slight timestamp discrepancies may occur due to podcast platform differences.BOOKS AND RESOURCESLewis Howes' book The School of Greatness.Gay Hendricks' Book The Big Leap.Gary Vaynerchuk's book Crushing It!Lori Greiner's book Invent It, Sell It, Bank It!All of Robert's favorite books.NEW TO THE SHOW?Check out our Millennial Investing Starter Packs.Browse through all our episodes (complete with transcripts) here.Try Robert's favorite tool for picking stock winners and managing our portfolios: TIP Finance.Enjoy exclusive perks from our favorite Apps and Services.Stay up-to-date on financial markets and investing strategies through our daily newsletter, We Study Markets.Learn how to better start, manage, and grow your business with the best business podcasts.SPONSORSGet a FREE audiobook from Audible.Learn how Principal Financial can help you find the right benefits and retirement plan for your team today.Get a customized solution for all of your KPIs in one efficient system with one source of truth. Download NetSuite's popular KPI Checklist, designed to give you consistently excellent performance for free.Invest in the same paintings available to billionaires, at a more accessible price point with Masterworks.Be confident that you'll be small businessing at your best with support designed to help you reach your goals. Book an appointment with a TD Small Business Specialist today.Shape and flex your home loans how you want with Athena. Join the thousands of Aussies taking control of their mortgage today.Enjoy an all-in-one personal finance app that gives you a comprehensive view of all your accounts, investments, transactions, cash flow, net worth, and more, with Monarch Money. Get an extended thirty-day free trial today.Learn from the world's best minds - anytime, anywhere, and at your own pace with Masterclass. Get 15% off an annual membership today.Your home might be worth more than you think. Earn extra money today with Airbnb.Support our free podcast by supporting our sponsors.Connect with Dan: Website|Instagram | Facebook | LinkedInConnect with Robert: Website | InstagramSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The guest is Ken Clausen, National Director of Attack Cancer for the HEADstrong Foundation. A 2010 graduate of the University of Virginia, Clausen was a four-time All-American with the Cavaliers, including three First Team selections. The 5th overall selection in the 2010 Major League Lacrosse draft by the Denver Outlaws, Clausen spent six seasons in the MLL, capturing a title with the Outlaws in 2014.

Im Rhein landet tagtäglich viel Müll. Müll, der an den Rheinstränden liegen gelassen oder sogar in den Rhein hinein geworfen wurde. Damit der nicht durch die Strömung ins Meer gelangt und dadurch unserer Umwelt, den Tieren und auch uns Menschen schadet, hat es sich der Kölner Verein Krake e.V. zur Aufgabe gemacht, so viel Müll wie möglich aus dem Fluss aufzufangen. Und das machen die freiwilligen Helfer:innen mit einer ganz besonderen schwimmenden Müllfalle: der Rheinkrake. Die funktioniert wie ein Sieb, denn die Strömung treibt die Abfälle durch ein Gitter mit großen Löchern in einen Fangkorb. Alle zwei Wochen wird die Rheinkrake geleert und diesmal darf Laura dabei sein und die Ehrenamtlichen tatkräftig unterstützen. Dabei findet sie nicht nur Müll, sondern Gegenstände, die in ihrer Werkstatt bestimmt noch Verwendung finden…

Außerdem: Schon wieder alle krank - Wie wird der Herbst mit Corona und co? (8:05)/ Welcher Müll ist in der Umwelt besonders schlimm? (13:40)// Mehr spannende Themen wissenschaftlich eingeordnet findet ihr hier: www.quarks.de // Kritik, Fragen? Schreibt uns! --> quarksdaily@wdr.de Von Sebastian Sonntag.

The In the Crease boys sit down with Devan Spilker, former Limestone player and MLL player for the Charlotte Hounds, to discuss a challenging situation that his family is facing. Devan explains not only how his family, and his son, Axel, have handled it, but how the lacrosse community has, once again, responded.  It is a MUST listen!If you like what we are doing, subscribe on your favorite podcast platform and help us spread the word of the great things happening in D2 Men's Lacrosse!Follow us at: Instagram: @in_the_crease_d2_lax Facebook: In the Crease with Danny and Kevin Twitter: @D2_Lax_podcast

Happy beginning of summer! ChatGPT isn't even a year old and we have seen the number of tools relying on AI grow exponentially since its inception. Is there something you want to try out before starting back in the fall? Here's what we have for you! In this episode Brent and Ixchell give you twelve AI tools to explore this summer at your leisure. Show Notes: www.DIESOL.org/87 Want to support the show? Leave us a review right here in your podcatcher! Subscribe on Patreon  or Buy us a Coffee Thank you!!

Philly Hall of Fame goaltending phenom Drew Adams shares his wise insights on “the journey” from Delco to the PLL and home again. Here are some notes to help you enjoy this new episode! After a high school All-American career Drew headed to Penn State University where he was ECAC Rookie of the Year, ECAC Goalie of the Year twice, and 3X USILA Honorable Mention All-American. Drew thrived as a professional playing for the MLL (Major Lacrosse League) New York Lizards where he played in six MLL All-Star games and won a League Championship in 2015. Additionally, he was MLL Goalie of the Year three times. He also played in the PLL for the Archers LC. On the international stage, Drew won a silver medal with Team USA in 2014. Since his retirement, Drew has been inducted into the eastern PA Chapter of the USA Lacrosse Hall of Fame and has been busy living and working in the Villanova/Delco area. We hope you enjoy the show. 6:00: For parents:  The even-keeled unconditional support from parents of student-athletes. Post-game in the Adams family. Subtle observations and support. 9:00: For coaches:  Goaltending: First save the ball. Be mentally tough. Lead the team. It's not a perfect science. Are there goalie non-negotiables? 17:56: For players:  Culture building with the MLL New York Lizards – they made sacrifices! The Team USA experience and dealing with, playing with, and enjoying the talent of the Canadians. Questions & Answers 24:50: Influential youth league and high school influential coaches. Coaches who made an impact growing up in a special community. 28:45: The tradition, the power, and the influence of Ridley lacrosse in the Philadelphia area. 31:17: The unfamiliar collegiate recruiting process – club influence and building confidence. 33:20: Choosing PSU and how the goalie recruiting process is different. PSU coaches made a difference. 37:14: PSU memories and heartbreaks. Trying to get “over the hump.” 39:00: Grant Ament and the foreshadowing commercial. A good full-circle story. 41:41: Finding mentors and finding one's stride professionally. 44:40: Brian “Doc” Dougherty and the power of a “goalie community”. 47:00: Transitioning from the MLL to the PLL. Pushing a new league forward. 48:30: Coach Bates, Coach Resch, and the Archers LC. Special times. 50:00: Top shooters and the challenges they bring for a goalie. Canadians – again! 52:50: Walking away from the game. Work and family calls. 54:54: Rapid Fire NXT Homework

The CPG Guys are joined by Vince Jones, SVP/GM and Global head of eCommerce at PepsiCo, whose are enjoyed by consumers more than one billion times a day in more than 200 countries and territories around the world. PepsiCo's product portfolio includes a wide range of enjoyable foods and beverages, including many iconic brands – such as Lay's, Doritos, Cheetos, Gatorade, Pepsi-Cola, Mountain Dew, Quaker and SodaStream – that generate more than $1 billion each in estimated annual retail sales.Follow Vince Jones on LinkedIn at: https://www.linkedin.com/in/jonesvince/Follow PepsiCo on LinkedIn at: https://www.linkedin.com/company/pepsico/ Follow PepsiCo online at: http://pepsico.com Vince answers the following questions:1) Your career journey after Stanford has been in operations first, then even CEO of ebags before leading the digital journey at PepsiCo especially as covid shaped. You have created long lasting legacies for the industry. Take us through the years and what's your advice for someone early in their career in the digital world?2) Why is retail media one of the most important spaces in the cpg and retail industry these days?3) How has ecommerce matured over the last 5 years in the grocery world? What is sticky these days and what should people focus on?4) How do you connect to the other arms of PepsiCo for surround sound amplification? How do you link back with marketing and selling commercial teams?5) What is the role of technology innovation these days? Is AI and MLL real or pretenders? How are you using these?6) The industry is largely still from a knowledge standpoint mostly brick & mortar. In this scenario, how do you coach other senior leaders on all aspects digital especially given winning in this space has as many tactical execution parameters as brick & mortar?7)  What are the latest instore digital technologies these days connecting back to the shopper omnichannel journey that drive outcomes for the consumer and the brand? Which ones do you personally feel the industry should be championing?8) Our last question always goes to fast forward …. what is your prediction around how RMN will evolve?  CPG Guys Website: http://CPGguys.comFMCG Guys Website: http://FMCGguys.comCPG Scoop Website: http://CPGscoop.comNextUp Website: http://nexupisnow.org/cpgguysRetailWit Website: http://retailwit.comDISCLAIMER: The content in this podcast episode is provided for general informational purposes only. By listening to our episode, you understand that no information contained in this episode should be construed as advice from CPGGUYS, LLC or the individual author, hosts, or guests, nor is it intended to be a substitute for research on any subject matter. Reference to any specific product or entity does not constitute an endorsement or recommendation by CPGGUYS, LLC. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.  CPGGUYS LLC expressly disclaims any and all liability or responsibility for any direct, indirect, incidental, special, consequential or other damages arising out of any individual's use of, reference to, or inability to use this podcast or the information we presented in this podcast.